OHSU Knight Cancer Institute

• Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder

  Phase 1, Recruiting, 6 people, 28 Sept 2026

• Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

  Phase 1, Recruiting, 40 people, 23 Apr 2026

• NCT07228273

  Phase 2, Recruiting, 102 people, 14 Nov 2025

• NCT06895473

  Phase 2, Recruiting, 26 people, 26 Mar 2025

• NCT06630325

  Phase 2, Terminated, 6 people, 8 Oct 2024

• NCT06504459

  Phase 2, Recruiting, 40 people, 16 Jul 2024

• NCT06357676

  Phase 1/2, Recruiting, 27 people, 10 Apr 2024

• NCT06357182

  Phase 1, Recruiting, 30 people, 10 Apr 2024

• NCT06320405

  Phase 1/2, Recruiting, 38 people, 20 Mar 2024

• NCT06249191

  Phase 1/2, Recruiting, 40 people, 8 Feb 2024

• NCT06157099

  Phase 2, Active, not recruiting, 150 people, 5 Dec 2023

• EMBRACE: Exercising Together

  Phase 2, Recruiting, 400 people, 22 Sept 2023

• NCT05705492

  Phase 2, Recruiting, 66 people, 30 Jan 2023

• Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

  Phase 1, Active, not recruiting, 13 people, 31 May 2022

• NCT05238831

  Early phase 1, Withdrawn, 0 people, 14 Feb 2022

• NCT04872790

  Phase 1, Active, not recruiting, 20 people, 5 May 2021

• NCT04539808

  Phase 2, Active, not recruiting, 42 people, 7 Sept 2020

• NCT04267887

  Phase 2, Active, not recruiting, 7 people, 13 Feb 2020

• NCT04251715

  Phase 2, Terminated, 5 people, 5 Feb 2020

• NCT03878524

  Phase 1, Terminated, 2 people, 18 Mar 2019

Sources: clinicaltrials.gov